Pasar al contenido principal

DESCIFRANDO LOS SUBTIPOS DE MICROGLIA DELETEREA POTENCIALMENTE RELEVANTES EN ENFERMEDADES NEURODEGENERATIVAS

PID2021-124096OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases

  • Fernández-Calle, Rosalía
  • Konings, Sabine C.
  • Frontiñán-Rubio, Javier
  • García-Revilla, Juan
  • Camprubí-Ferrer, Lluís
  • Svensson, Martina
  • Martinson, Isak
  • Boza-Serrano, Antonio
  • Venero, José L.
  • Nielsen, Henrietta M.
  • Gouras, Gunnar K.
  • Deierborg, Tomas
ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer's disease (AD). Neuroinflammation has become the third hallmark of AD, together with Amyloid-β plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein. This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE's single-nucleotide polymorphisms affect its structure, function, and involvement during health and disease. This review reflects on how APOE's polymorphisms impact critical aspects of AD pathology, such as the neuroinflammatory response, particularly the effect of APOE on astrocytic and microglial function and microglial dynamics, synaptic function, amyloid-β load, tau pathology, autophagy, and cell-cell communication. We discuss influential factors affecting AD pathology combined with the APOE genotype, such as sex, age, diet, physical exercise, current therapies and clinical trials in the AD field. The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation, e.g., alpha- synucleinopathies and Parkinson's disease, traumatic brain injury, stroke, amyotrophic lateral sclerosis, and multiple sclerosis, is also addressed. Therefore, this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field., Open access funding provided by Lund University. This work was supported by The Strategic Research Area MultiPark (Multidisciplinary Research in neurodegenerative diseases) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, Crafoord Foundation, Swedish Dementia Association, G&J Kock Foundation, Olle Engkvist Foundation, the Swedish Medical Research Council, the Swedish Parkinson Foundation, the A.E. Berger Foundation, the Thurings Foundation, and the Swedish mental health foundation to T.D., M.S, A.B-S. The Royal Physiographic Society of Lund grant to R.F–C. SYNDEGEN, Marie Curie grant n°721802 to G.K.G and S.K. We also thank the Spanish Ministerio de Ciencia e Innovación/FEDER/UE/PID2021-124096OB-I00; the Spanish Junta de Andalucia/FEDER/EU P18-RT-1372 and the Spanish FEDER I + D + i-USE US-1264806 to J.L.V., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration

  • García-Revilla, Juan
  • Boza-Serrano, Antonio
  • Espinosa-Oliva, Ana M.
  • Sarmiento, Manuel
  • Deierborg, Tomas
  • Ruiz, Rocío
  • Martínez de Pablos, Rocío
  • Burguillos, Miguel Ángel
  • Venero, José L.
The advent of high-throughput single-cell transcriptomic analysis of microglia has revealed different phenotypes that are inherently associated with disease conditions. A common feature of some of these activated phenotypes is the upregulation of galectin-3. Representative examples of these phenotypes include disease-associated microglia (DAM) and white-associated microglia (WAM), whose role(s) in neuroprotection/neurotoxicity is a matter of high interest in the microglia community. In this review, we summarise the main findings that demonstrate the ability of galectin-3 to interact with key pattern recognition receptors, including, among others, TLR4 and TREM2 and the importance of galectin-3 in the regulation of microglia activation. Finally, we discuss increasing evidence supporting the involvement of this lectin in the main neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, and stroke., We thank the Spanish Ministerio de Ciencia, Innovación y Universidades/FEDER/UE RTI2018-098645-B-100, PID2019-107948RA-I00 and RYC-2017-21804; the Agencia Española de Investigación PID2021-124096OB-I00 and PID2021-126090OA-I00; the Spanish Junta de Andalucia /FEDER/EU P18-RT-1372 and the Spanish FEDER I + D + i-USE US-1264806, US-1264152 and US-1265062 from University of Seville. This work has also been supported by the Strategic Research Area MultiPark (Multidisciplinary Research focused on neurodegenerative diseases) at Lund University, the Swedish Alzheimer foundation, the Swedish Brain Foundation, the Crafoord Foundation, the Swedish Dementia Association, the G&J Kock Foundation, the Olle Engkvist Foundation, the Swedish Research Council (Project 2019-06333), the Royal Physiographic Society (42222 and 40594), the A.E. Berger Foundation, the Swedish Parkinson Foundation and the Medical Faculty at Lund University. Open access funding provided by Lund University., Peer reviewed